Leqvio (inclisiran) — HCPCS J1306

CARECOST ESTIMATE · BILLING CHEAT SHEET

Novartis (licensed from Alnylam) 284 mg/1.5 mL single-dose prefilled syringe **Subcutaneous — NOT infusion** Once, 3mo, then q6mo

ASP: Q3 2026

HCPCS	FIXED DOSE	MODIFIER	ADMIN CPT	MEDICARE ASP+6%
J1306	**284 units**	**JZ (usual) · TB**	**96372**	**$12.905**
1 unit = 1 mg	284 mg · no wt-based math	JG retired 1/1/2025	subQ injection — NOT 96365/96413	/mg · $3,581.24/284 mg dose

NOT AN INFUSION. Leqvio is a subQ injection billed with **96372** only. No boxed warning; label carries a hypersensitivity/anaphylaxis warning and a contraindication for prior serious hypersensitivity to inclisiran or its excipients.

CODES, NDC & MECHANISM

HCPCS	`J1306` — "Injection, inclisiran, 1 mg"
GENERIC	inclisiran sodium (siRNA; GalNAc-conjugated; PCSK9 mRNA silencer)
NDC	`0078-1000-60` (284 mg/1.5 mL PFS) — Novartis, labeler 0078. DailyMed-verified.
NOT THE SAME AS	PCSK9 monoclonal antibodies Repatha (evolocumab) / Praluent (alirocumab) — different mechanism, different code, different schedule

SAMPLE CMS-1500 LINE (PER NOVARTIS BILLING GUIDE)

24A shaded (NDC)	`N400078100060ML1.5`
Line 1	`J1306 · JZ · 284 units`
Line 2	`96372 · 1 unit`

340B: TB only in 2026. JG retired for ALL 340B-covered entities effective 1/1/2025 (CMS MLN4800856); Novartis sample forms show TB alongside J1306.

DOSING SCHEDULE (FIXED — NO MG/KG MATH)

DOSE	TIMING	UNITS
284 mg SC	Day 1 (initial)	`J1306 × 284`
284 mg SC	Month 3	`J1306 × 284`
284 mg SC	Every 6 months after	`J1306 × 284`

Missed >3 months: restart initial-then-3-month schedule. No weight/renal/hepatic dose adjustment per label.

ICD-10 (REPRESENTATIVE — SEE FULL NOVARTIS LIST)

CODE	FOR
`E78.00`	Pure hypercholesterolemia, unspecified
`E78.011 / E78.010`	HeFH / HoFH
`I25.10, I21.4, I63.9, I70.x`	ASCVD (examples)
`E11, N18, I10`	Diabetes / CKD / HTN (risk factors)
`Z83.42`	Family history of FH

ADMINISTRATION & MODIFIERS

CODE	WHEN
`96372`	**Every administration** — SC/IM therapeutic injection
`96365 / 96413 / 96401`	**NOT APPROPRIATE** — not an infusion, not chemo

#1 error: defaulting to an infusion admin code out of habit. Leqvio has zero infusion time.

PA / STEP THERAPY — UHC EXAMPLE (VERIFY PER PLAN)

- Dx: HeFH, ASCVD, or primary hyperlipidemia
- **AND** documented statin trial OR prior PCSK9 mAb use
- **AND separately**: documented PCSK9 mAb failure/contraindication/intolerance
- LDL-C ≥ 55 mg/dL; prescriber = cardiology/endo/lipid specialist
- NOT combined with a PCSK9 inhibitor; initial auth ≤12 months

SOURCING & PATIENT ASSISTANCE

- **Buy-and-bill OR specialty pharmacy** — confirm required channel per payer before ordering
- **LEQVIO Co-pay Program:** commercial pts as low as $0/tx; T&Cs apply; not valid for govt insurance
- LEQVIO Service Center: 833-LEQVIO2 (833-537-8462); LEQVIOhcp.com

TOP DENIALS: (1) infusion/chemo admin code used instead of 96372; (2) wrong sourcing channel for the payer; (3) missing PCSK9-failure documentation on PA; (4) billed while patient still on a PCSK9 inhibitor; (5) LDL-C threshold not documented; (6) JG used instead of TB on a 340B claim.

Sources: DailyMed / FDA label (NDA 214012), Novartis LEQVIO Billing and Coding Guide, CMS ASP Q3 2026, CMS 340B modifier guidance (MLN4800856), UnitedHealthcare commercial drug policy 2026D0101L, leqvio.com. Verify against your own source documents before billing.